AT&T-Led Neutral-Host Network Powers New Connectivity Experience at Davis Wade Stadium August 10, 2026 AT&T customers at Mississippi State University’s Davis Wade Stadium in Starkville are getting a boost in wireless connectivity following the deployment of a new AT&T-led distributed antenna system, or DAS, powered by Airspan’s MobileAccess 6000 Digital platform. Led and owned by AT&T as a neutral-host network, the new DAS is designed to deliver high-capacity, multi-operator [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results August 10, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial [...]
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera August 9, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call [...]
Targa Newfoundland Unveils Full Sponsor Ecosystem, Announces Lives Showcase at IBC 2026 Amsterdam August 7, 2026 Dejero, ADLINK Technology, Eutelsat and Intel among the sponsors powering the first-ever livestream of North America's only tarmac rally, with a live demonstration at IBC and a video message from professional racing driver Randy Pobst.
Algoma Central Corporation Reports Financial Results for the 2026 Second Quarter August 7, 2026 Strategic acquisitions, expanded credit facilities, and strong segment performance position Algoma for continued growth.
Sia Accelerates Its Expansion in Australia with the Acquisition of Seven Consulting August 7, 2026 Sia continues its international expansion with the acquisition of Seven Consulting, an Australian management consulting firm known for its expertise in Business Transformation, serving many of the country’s largest Banking, Government, Transportation & Postal, Retail & Consumer Goods, and Energy & Utilities organisations. Founded in 2002, Seven Consulting brings together a team of over 100 [...]
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets August 7, 2026 2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 [...]
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights August 6, 2026 Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in The Lancet Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months
Vercel Appoints Amit Agarwal, Standard Template Labs CEO and former Datadog President, to Board of Directors August 6, 2026 The product leader who helped scale Datadog from early-stage startup through IPO brings deep product expertise to Vercel's board